As a new Delta plus variant is identified, India’s exemption of bridging trials for imported COVID-19 vaccines could help speed up immunization efforts. The urgency to fully immunize individuals could also prompt a reduction in the interval between Serum/AstraZeneca’s COVID-19 vaccine doses
As if the Delta variant wasn’t enough, a Delta plus variant of SARS-CoV-2 has been recently identified and while it’s only causing the scientific community to take note as of now, it could soon cause governments across the world to hasten their immunization efforts.
On 13 June, clinician and scientist at Delhi's CSIR-Institute of Genomics and Integrative Biology (IGIB), Vinod Scaria tweeted "One of the emerging variants is B.1.617.2.1 also known as AY.1 characterized...
Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.
